Treace Medical (NASDAQ: TMCI) posts 2025 prelim results, presentation

Rhea-AI Filing Summary

Treace Medical Concepts reported that it has released certain preliminary unaudited financial results for the quarter and year ended December 31, 2025. These results are shared through a press release furnished as an exhibit and are not treated as formally filed financial statements. The company also posted an updated investor presentation on its investor relations website.

Treace plans to use this presentation in meetings with analysts and investors, including at the J.P. Morgan Healthcare Conference on January 14, 2026 at 7:30 a.m. Pacific Time / 10:30 a.m. Eastern Time. A live webcast of this event, along with an archived recording and the presentation, will be available in the Investors section of the company’s website.

false000163062700016306272026-01-132026-01-13

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 13, 2026

TREACE MEDICAL CONCEPTS, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-40355		47-1052611
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification Number)

100 Palmetto Park Place

Ponte Vedra, Florida 32081

(Address of principal executive offices, including Zip Code)

Registrant’s telephone number, including area code: (904) 373-5940

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value per share		TMCI		The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On January 13, 2026, Treace Medical Concepts, Inc. (the "Company") issued a press release regarding certain preliminary unaudited financial results for the quarter and the year-ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

This information furnished under this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 7.01. Regulation FD Disclosure.

On January 13, 2026, the Company posted an investor presentation, which may be accessed through its investor relations website. A copy of the presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated by reference herein. The Company intends to use this presentation in meetings with analysts, investors and others from time to time, including at the J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 7:30 am Pacific Time / 10:30 am Eastern Time. A live webcast of this event, as well as an archived recording and presentation, will be available in the Investors section of the Company's website.

The information furnished under this Item 7.01, including Exhibit 99.2, shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 (d) Exhibits	Financial Statements and Exhibits.
Exhibit No.		Description
99.1		Press Release of Treace Medical Concepts, Inc. issued on January 13, 2026
99.2		Investor Presentation, dated January 13, 2026 (furnished pursuant to Item 7.01)
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				TREACE MEDICAL CONCEPTS, INC.
Date: January 13, 2026				By:		/s/ Mark L. Hair
						Mark L. Hair
						Chief Financial Officer

FAQ

What did Treace Medical Concepts (TMCI) disclose in this 8-K filing?

Treace Medical Concepts furnished a press release with certain preliminary unaudited financial results for the quarter and year ended December 31, 2025, and an updated investor presentation that it will use in meetings with analysts, investors and others.

Which period do the preliminary Treace Medical Concepts (TMCI) results cover?

The preliminary unaudited financial results relate to the quarter and the full year ended December 31, 2025.

Where can investors access Treace Medical Concepts’ (TMCI) press release and presentation?

The press release is furnished as Exhibit 99.1 and the investor presentation as Exhibit 99.2 to the report, and the presentation can also be accessed through the Investors section of the company’s website.

How will Treace Medical Concepts (TMCI) use the new investor presentation?

The company intends to use the investor presentation in meetings with analysts, investors and others from time to time, including at the J.P. Morgan Healthcare Conference.

When is Treace Medical Concepts (TMCI) presenting at the J.P. Morgan Healthcare Conference?

The company plans to present on Wednesday, January 14, 2026 at 7:30 a.m. Pacific Time / 10:30 a.m. Eastern Time, with a live webcast and archived recording available in the Investors section of its website.

Are Treace Medical Concepts’ (TMCI) preliminary results considered filed financial statements?

No. The information furnished under Items 2.02 and 7.01, including Exhibits 99.1 and 99.2, is expressly stated as not deemed “filed” for purposes of Section 18 of the Exchange Act or incorporated into other Securities Act or Exchange Act filings unless specifically referenced.